Showing results (2031-2040 of 2,359) with videos related to

Sort By:
Pageof 236
European Radiology|June 19, 2024
The prognostic importance of traumatic axonal injury on early MRI: the Trondheim TAI-MRI grading and quantitative modelsKent Gøran Moen, Anne-Mari Holte Flusund, Hans Kristian Moe, et al.
Foods (Basel, Switzerland)|October 28, 2023
Lipid Profile in Multiple Sclerosis: Functional Capacity and Therapeutic Potential of Its Regulation after Intervention with Epigallocatechin Gallate and Coconut OilJose Enrique de la Rubia Ortí, Jose Luis Platero Armero, María Cuerda-Ballester, et al.
FASEB Journal : Official Publication of the Federation of American Societies for Experimental Biology|April 4, 2026
Testosterone Exposure During Fetal Masculinization Programming Window Determines the Kidney Size in Adult MiceArttu Junnila, Kalle T Rytkönen, Guillermo Martinez-Nieto, et al.
Plos One|February 7, 2018
Investigation of single and synergic effects of NLRC5 and PD-L1 variants on the risk of colorectal cancerCalogerina Catalano, Miguel Inacio da Silva Filho, Christoph Frank, et al.
Environment International|January 7, 2026
Assessing the severe urban pollution crisis in Sarajevo, Bosnia and Herzegovina: mobile measurements and source characterizationMichael Bauer, Jay G Slowik, Marta Via, et al.
Nutrients|December 16, 2020
Possible Reduction of Cardiac Risk after Supplementation with Epigallocatechin Gallate and Increase of Ketone Bodies in the Blood in Patients with Multiple Sclerosis. A Pilot StudyMaría Benlloch, María Cuerda Ballester, Eraci Drehmer, et al.
Rheumatology (Oxford, England)|September 29, 2017
Comparing biosimilar SB2 with reference infliximab after 54 weeks of a double-blind trial: clinical, structural and safety resultsJosef S Smolen, Jung-Yoon Choe, Nenad Prodanovic, et al.
Annals of the Rheumatic Diseases|October 19, 2017
Safety, immunogenicity and efficacy after switching from reference infliximab to biosimilar SB2 compared with continuing reference infliximab and SB2 in patients with rheumatoid arthritis: results of a randomised, double-blind, phase III transition studyJosef S Smolen, Jung-Yoon Choe, Nenad Prodanovic, et al.
Physical Review Letters|October 29, 2013
Discovery of a superhard iron tetraboride superconductorHuiyang Gou, Natalia Dubrovinskaia, Elena Bykova, et al.
Annals of the Rheumatic Diseases|August 31, 2015
A randomised, double-blind, phase III study comparing SB2, an infliximab biosimilar, to the infliximab reference product Remicade in patients with moderate to severe rheumatoid arthritis despite methotrexate therapyJung-Yoon Choe, Nenad Prodanovic, Jaroslaw Niebrzydowski, et al.
Pageof 236